Abstract
Transcatheter aortic valve replacement (TAVR) is a viable alternative for patients with symptomatic severe aortic stenosis. Acute myocardial infarction is a contraindication to TAVR. The efficacy of emergency TAVR combined with percutaneous coronary intervention for patients presenting with acute myocardial infarction, severe aortic stenosis, and cardiogenic shock remains an explorable subject.